We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cello Health Plc | LSE:CLL | London | Ordinary Share | GB00B0310763 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 161.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 161.00 | GBX |
Cello Health (CLL) Share Charts1 Year Cello Health Chart |
|
1 Month Cello Health Chart |
Intraday Cello Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/8/2020 | 15:24 | Cello - solid prospects | 1,087 |
| 29/1/2015 | 16:56 | CELLO GROUP? | 9 |
| 12/1/2005 | 16:17 | Cello or EQI? | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 02/7/2020 16:41 by coopstock Why would anyone buy at 163p - when agreed price is 161p? Am I missing something? |
Posted at 05/6/2020 15:40 by qs99 US market recovery and economic news today, may help CLL....let's see |
Posted at 04/6/2020 11:36 by qs99 Having to pay full offer price....DYOR....loo |
Posted at 20/5/2020 08:39 by davebowler Cenkos-Navigating positively through disruptions Cello’s AGM statement should reassure that FY20 trading to date remains robust, underpinned by “solid” growth in net revenue in Q1/20. While Q2/20 saw certain early disruption, overall progress has been made to maintain revenues alongside effective cost controls, thus a creditable H1/20E result is expected. The 23% fall in the shares since February’s highs, appears to overly discount for the actual reality of this disruption. Despite some disruption in Q2/20, the Cello Health division continues to perform: Q1/20: Cello Health delivered “strong” overall net revenue and profit growth over Q1/20, benefitting from ISS’s acquisition in August 2019. On a LFL basis, excluding ISS, organic growth has been described as “good”, continuing recent momentum. Q2/20: Commentary on trading post the COVID-19 outbreak suggests of continued progress, with new win rates being maintained, leading to a continuation of the typical six month visibility to bookings going into H2/20. This comes despite some disruption in activities requiring physical proximity (healthcare conventions, expert focus groups etc), which are being digitally delivered or have been put on hold. Some COVID-19 benefits: New projects have arisen as result of the pandemic, with Cello Connect, the digital and creative marketing capability transferred from Signal, delivering COVID-19 related public health campaigns, while newly acquired ISS is also benefitting from new US regulatory drug approvals and FDA fillings. Signal expected to be more impacted, but it’s far less material this year: Cello Signal generated only 16% of net revenue in Q1/20 following Connect’s transfer at the start of the year. Over Q2/20 and beyond, trading is unsurprisingly expected to be challenged by COVID-19, given certain clients are engaged in troubled sectors (eg travel, leisure), thus some delays and cancellations are expected. As such, cost control measures have, and continue to be undertaken, where necessary. Balance sheet remains strong: Today’s update confirms Cello maintains a “solid” net cash position. This comes despite a seasonal working capital outflow in Q1/20 and is inclusive of a £0.7m payment for the final earn-out payment on Defined Health and FY19A’s £1.1m final dividend. The implies positive cash generation to date this year. Valuation: Prior to the COVID-19 outbreak, Cello traded at a forward P/E of 16.0x in late February, a multiple we feel is merited. If Cello were to deliver a FY20E result largely consistent with FY19A, a price today of 151p p/s (+32% upside) would be fair. |
Posted at 07/4/2020 12:37 by coopstock Cutting the dividend just one week after announcing the award of all those new share options for senior directors. All in this together - I don't think so. Pretty poor. |
Posted at 23/3/2020 09:02 by qs99 Any vague return to normality and given HNT purchase recently, IMO this will get bought out if it stays at this price.DYOR |
Posted at 03/3/2020 12:18 by zipstuck As the major drug companies are being squeezed on supply chains you have to wonder how this might affect CLL |
Posted at 09/1/2020 21:32 by bargainbob Poikka glad i introduced a little Fanny to the advfn boards and it boosted the share price to heights not seen before.Good luck reaching 150p |
Posted at 08/1/2020 17:33 by f15jcm I bought for a new position today. With the price at 140p I figured my 17,500 shares would push the price to 12y highs, which seems to have worked. |
Posted at 07/1/2020 08:30 by davr0s Who knows but I buy breakouts like this any day of the week. Shares that are going to go and make big gains have to break out first. No idea where price will end up but gotta be in the game to capture some of these |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
